DISCLOSURE NOTICE: The information contained in this release is as of November 18, 2013. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.This release contains forward-looking information about XELJANZ (tofacitinib citrate), including its potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, uncertainties related to the extent of market acceptance in the U.S.; whether and when the FDA will assess the benefit: risk profile of the 10 mg twice-daily dose and the impact of XELJANZ on the inhibition of structural damage; and competitive developments.
Pfizer Announces FDA Approval Of Supplemental Application To Expand XELJANZ® (tofacitinib Citrate) Labeling To Include Additional Patient-Reported Outcomes Data For Adults With Moderately To Severely Active Rheumatoid Arthritis
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.